23andMe (ME) Stock Forecast & Price Target $0.50 -0.27 (-35.32%) Closing price 03/28/2025 08:00 PM EasternExtended Trading$0.50 0.00 (0.00%) As of 03/28/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock 23andMe - Analysts' Recommendations and Stock Price Forecast (2025) How MarketBeat Calculates Price Target and Consensus Rating MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data. Consensus Rating ReduceBased on 2 Analyst RatingsSell1Hold1Buy0 Based on 2 Wall Street analysts who have issued ratings for 23andMe in the last 12 months, the stock has a consensus rating of "Reduce." Out of the 2 analysts, 1 has given a sell rating, and 1 has given a hold rating for ME. Consensus Price Target $9.401,787.55% Upside According to the 2 analysts' twelve-month price targets for 23andMe, the average price target is $9.40. The highest price target for ME is $9.40, while the lowest price target for ME is $9.40. The average price target represents a forecasted upside of 1,787.55% from the current price of $0.50. Get the Latest News and Ratings for ME and Related Stocks Enter your email address to receive the latest news and analysts' ratings for 23andMe and its competitors. Enter your email to sign up for newsletter Sign Up ME Analyst Ratings Over TimeTypeCurrent Forecast4/1/24 to 4/1/251 Month Ago3/2/24 to 3/2/253 Months Ago1/2/24 to 1/1/251 Year Ago4/2/23 to 4/1/24Strong Buy0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)Buy0 Buy rating(s)0 Buy rating(s)0 Buy rating(s)1 Buy rating(s)Hold1 Hold rating(s)1 Hold rating(s)1 Hold rating(s)0 Hold rating(s)Sell1 Sell rating(s)1 Sell rating(s)1 Sell rating(s)0 Sell rating(s)Consensus Price Target$9.40$9.40$9.40$35.00Forecasted Upside1,787.55% Upside327.27% Upside189.23% Upside232.07% UpsideConsensus RatingReduceReduceReduceBuy Remove Ads ME Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History ME Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table 23andMe Stock vs. The CompetitionType23andMeMedical CompaniesS&P 500Consensus Rating Score 1.50 2.82 2.54Consensus RatingReduceModerate BuyModerate BuyPredicted Upside1,787.55% Upside19,290.07% Upside19.04% UpsideNews Sentiment RatingNeutral NewsSee Recent ME NewsPositive NewsPositive News Remove Ads Recent Analyst Forecasts and Stock Ratings All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Years 5 Years Time Frame Start Date End Date Most Recent from Each Brokerage All Show Export to Excel DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails3/22/2025Weiss Ratings0 of 5 stars Reiterated RatingSell (E+) ➝ Sell (E+)8/7/2024TD Cowen4 of 5 starsS. MahSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Strong Sell4/16/2024Citigroup3 of 5 stars Lower TargetNeutral ➝ Neutral$17.00 ➝ $9.40+17.47%Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 09:38 AM ET. ME Forecast - Frequently Asked Questions What is 23andMe's forecast for 2025? According to the research reports of 2 Wall Street equities research analysts, the average twelve-month stock price forecast for 23andMe is $9.40, with a high forecast of $9.40 and a low forecast of $9.40. Should I buy or sell 23andMe stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for 23andMe in the last year. There is currently 1 sell rating and 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "reduce" ME shares. Does 23andMe's stock price have much upside? According to analysts, 23andMe's stock has a predicted upside of 1,787.55% based on their 12-month stock forecasts. What analysts cover 23andMe? 23andMe has been rated by research analysts at Weiss Ratings in the past 90 days. Do Wall Street analysts like 23andMe more than its competitors? Analysts like 23andMe less than other "medical" companies. The consensus rating for 23andMe is Reduce while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how ME compares to other companies. Stock Forecasts and Research Tools Related Companies Anebulo Pharmaceuticals Stock Forecast VolitionRx Stock Forecast CytomX Therapeutics Stock Forecast Metagenomi Stock Forecast Gain Therapeutics Stock Forecast Aligos Therapeutics Stock Forecast Adaptimmune Therapeutics Stock Forecast Kronos Bio Stock Forecast Actinium Pharmaceuticals Stock Forecast Tenaya Therapeutics Stock Forecast Today's Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter This page (NASDAQ:ME) was last updated on 4/1/2025 by MarketBeat.com Staff From Our PartnersNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | SponsoredNew “Trump” currency proposed in DCA former U.S. Presidential Advisor has come forward with a stern warning to investors: “Get out of tech, no...Paradigm Press | SponsoredIs Fort Knox Hiding Less Gold Than We Think? Find Out What That Means for YouWith gold prices recently soaring to record highs over $3,000 an ounce, and central banks rushing to accumulat...The Oxford Club | SponsoredTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredLive Footage From Elon Musk’s “Area 51”What’s happening inside this nondescript building in South Memphis is so incredible… That Elon’s competitor...Brownstone Research | Sponsored10X Bigger than AI, quantum, EVs, crypto, and robotics combined?World Economic Forum: "Arguably the Most Exciting Human Discovery Since Fire" Sam Altman, Bill Gates, and M...Stansberry Research | SponsoredTermination: 18F (read immediately)Have you ever heard of the government's 18F program? It helped manage digital services across the governmen...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 23andMe Holding Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share 23andMe With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ME Stock Free ME Stock Alerts